Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VIVACTIL vs AMITRIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, thereby increasing their synaptic concentrations. It also blocks histamine H1, alpha-1 adrenergic, and muscarinic receptors.
Major depressive disorder
Major depressive disorder,Neuropathic pain,Fibromyalgia,Migraine prophylaxis,Chronic tension-type headache,Insomnia (off-label),Irritable bowel syndrome (off-label)
10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.
Adults: Initial 25 mg PO once daily at bedtime, increase by 25 mg every 3-7 days as tolerated to typical maintenance 75-150 mg/day PO divided doses or single dose at bedtime. Maximum 300 mg/day.
Terminal elimination half-life ranges 18–34 hours (mean ~25 hours); clinical steady-state achieved within 5–7 days.
Terminal elimination half-life: 15–25 hours (mean 20 h); may extend to >40 h in elderly or hepatic impairment.
Primarily hepatic via CYP2D6 and other microsomal enzymes; active metabolite desmethylprotriptyline.
Hepatic, primarily via CYP2D6 and CYP3A4, with contributions from CYP1A2 and CYP2C19. Amitriptyline is metabolized to nortriptyline (active) and other metabolites.
Primarily renal (approximately 70% as metabolites, <5% unchanged), with the remainder via fecal/biliary elimination.
Renal: ~70% as metabolites, <5% unchanged; fecal: ~30% via bile.
Approximately 90% bound, primarily to albumin and α1-acid glycoprotein.
90–95% bound to albumin and alpha-1-acid glycoprotein.
Vd approximately 8–15 L/kg, indicating extensive tissue distribution with higher CNS concentration than plasma.
Vd: 15–30 L/kg; extensive tissue distribution, including CNS.
Oral bioavailability approximately 30–40% due to first-pass metabolism (extensive hepatic cytochrome P450 biotransformation).
Oral: 30–60% due to first-pass metabolism.
For GFR <10 m L/min: use with caution and consider 50% dose reduction; no specific guidelines for GFR 10-50 m L/min.
GFR 30-59 m L/min: Reduce dose by 50%. GFR 15-29 m L/min: Reduce dose by 75%. GFR <15 m L/min: Contraindicated. Hemodialysis: Not dialyzable; avoid use.
Child-Pugh class B or C: reduce dose by 50-75%; avoid use in severe hepatic impairment.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Use contraindicated or reduce dose by 75% with extreme caution.
Not recommended for children <12 years; for adolescents 12-18 years: 5-10 mg orally twice daily, max 60 mg/day.
Children ≥12 years: Initial 25-50 mg/day PO, increase gradually to 100 mg/day in divided doses. Children 6-11 years: 1-3 mg/kg/day PO in divided doses, not to exceed 100 mg/day. Not recommended under 6 years.
Initiate at 5 mg orally twice daily; increase slowly with monitoring for orthostatic hypotension and anticholinergic effects.
Initial 10-25 mg PO at bedtime, with gradual titration. Maintenance often 50-100 mg/day. Monitor for orthostatic hypotension, falls, and anticholinergic effects.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Amitriptyline is not approved for use in pediatric patients. Clinical worsening and suicide risk: Monitor for clinical worsening, suicidality, or unusual changes in behavior during initial therapy. Serotonin syndrome: Serotonin syndrome has been reported with SSRIs and SNRIs.
Activation of mania/hypomania,Seizure threshold lowering,Cardiovascular toxicity (QT prolongation, arrhythmias),Angle-closure glaucoma,Urinary retention,Hepatic impairment,Concomitant MAOI use
Suicidality in children, adolescents, and young adults; serotonin syndrome; activation of mania/hypomania; seizures; angle-closure glaucoma; urinary retention; cardiovascular effects (QT prolongation, arrhythmias); impaired cognitive/motor performance.
Hypersensitivity to protriptyline,Recent myocardial infarction,Concurrent MAOI therapy,QT prolongation or concomitant QT-prolonging drugs
Hypersensitivity to amitriptyline or any component; concomitant use with MAOIs or within 14 days of MAOI use; recent myocardial infarction; during acute recovery phase after MI; concomitant use with cisapride.
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products, soy sauce) if taking with MAOIs; however, protriptyline alone has no significant tyramine interaction. Grapefruit juice may increase protriptyline levels; avoid high intake. Alcohol can potentiate CNS depression. High-fiber foods may slightly reduce absorption; take at same time each day.
Avoid grapefruit and grapefruit juice as they may increase serum levels of amitriptyline. Limit tyramine-rich foods (aged cheeses, cured meats, fermented products) if taking MAOIs concurrently (contraindicated). Alcohol consumption may enhance sedative effects and is not recommended. High-fat meals may delay absorption but do not significantly alter overall exposure.
First trimester: Limited data; possible association with cardiovascular malformations. Second trimester: No specific malformations reported. Third trimester: Risk of neonatal withdrawal, respiratory distress, tachycardia, and hyperirritability if used near term.
First trimester: Possible increased risk of cardiovascular malformations (OR ~1.2-1.5). Second/third trimester: Risk of neonatal withdrawal syndrome (irritability, feeding difficulties) and direct toxic effects (tachycardia, urinary retention). Late third trimester: Possible persistent pulmonary hypertension of the newborn (PPHN) with SSRI-like effects, though data limited for tricyclics.
Present in breast milk; M/P ratio 0.5–1.9. Cases of drowsiness and poor feeding in infants reported; avoid breastfeeding or use with caution.
M/P ratio approximately 1.0-1.5. Excreted in breast milk in low amounts. Infant serum levels are usually subtherapeutic but cases of drowsiness, irritability reported. Use with caution; monitor infant for sedation and feeding difficulties. American Academy of Pediatrics considers compatible with breastfeeding if infant is healthy and full-term.
Decreased plasma concentrations due to increased volume of distribution; consider dose adjustment based on clinical response and serum levels; start at low dose and titrate.
Due to increased plasma volume and hepatic metabolism in pregnancy, lower serum concentrations may occur. Monitor clinical response; dose adjustments may be needed but no standard guidelines. Use lowest effective dose. Taper if discontinuing to avoid withdrawal.
VIVACTIL (protriptyline) is a tricyclic antidepressant with a more activating profile; it has the fastest onset of weight gain among TCAs. It is often used for ADHD, narcolepsy, and depression with psychomotor retardation. Due to its long half-life (54-92 hours), dosing should be conservative in elderly. It has a high anticholinergic burden, risking urinary retention and cognitive impairment in older adults. Avoid in patients with recent MI or arrhythmias. Monitor EKG and drug levels in suspected overdose.
For neuropathic pain, start at 10-25 mg at bedtime; titrate slowly to reduce sedative effects. Monitor QTc interval at baseline and with dose increases, especially in patients with cardiac risk factors. Anticholinergic effects (dry mouth, constipation) are common; consider prophylactic stool softeners. Avoid abrupt discontinuation; taper over 2-4 weeks to prevent withdrawal symptoms.
Take exactly as prescribed; do not stop suddenly as withdrawal may occur.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any suicidal thoughts or worsening depression immediately.,May cause dry mouth, constipation, blurred vision; use sugarless candy or gum for dry mouth.,Rise slowly from sitting or lying to prevent dizziness.,Do not take with MAOIs or within 14 days of stopping them.,Notify doctor if you experience fast/irregular heartbeat, difficulty urinating, or seizures.
Take exactly as prescribed, usually once daily at bedtime due to drowsiness.,Do not stop suddenly; taper under doctor's guidance to avoid nausea, headache, or insomnia.,Avoid alcohol and other CNS depressants (e.g., sedatives, opioids) as they increase sedation risk.,Report any signs of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate) or cardiac symptoms (e.g., palpitations, fainting).,May cause dry mouth, constipation, blurred vision; use sugar-free gum, hydrate, and consider fiber supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VIVACTIL vs AMITRIL, answered by our medical review team.
VIVACTIL is a Tricyclic Antidepressant that works by Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.. AMITRIL is a Tricyclic Antidepressant that works by Amitriptyline inhibits the reuptake of serotonin and norepinephrine, thereby increasing their synaptic concentrations. It also blocks histamine H1, alpha-1 adrenergic, and muscarinic receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VIVACTIL and AMITRIL depend on the specific clinical indication. These are both Tricyclic Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VIVACTIL is: 10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.. The standard adult dose of AMITRIL is: Adults: Initial 25 mg PO once daily at bedtime, increase by 25 mg every 3-7 days as tolerated to typical maintenance 75-150 mg/day PO divided doses or single dose at bedtime. Maximum 300 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VIVACTIL and AMITRIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VIVACTIL is classified as Category C. First trimester: Limited data; possible association with cardiovascular malformations. Second trimester: No specific malformations reported. Third trimester: Risk of neonatal withd. AMITRIL is classified as Category C. First trimester: Possible increased risk of cardiovascular malformations (OR ~1.2-1.5). Second/third trimester: Risk of neonatal withdrawal syndrome (irritability, feeding difficul. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.